1. "Golgi-customized Trojan horse" nanodiamonds impair GLUT1 plasma membrane localization and inhibit tumor glycolysis.
- Author
-
Kang B, Wang H, Jing H, Dou Y, Krizkova S, Heger Z, Adam V, and Li N
- Subjects
- Humans, Cell Line, Tumor, Neoplasms drug therapy, Neoplasms metabolism, Neoplasms pathology, Animals, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Glucose metabolism, Glycolysis drug effects, Golgi Apparatus metabolism, Golgi Apparatus drug effects, Cell Membrane metabolism, Cell Membrane drug effects, Glucose Transporter Type 1 metabolism, Apigenin administration & dosage, Apigenin pharmacology, Tellurium administration & dosage
- Abstract
Nutrient or energy deprivation, especially glucose restriction, is a promising anticancer therapeutic approach. However, establishing a precise and potent deprivation strategy remains a formidable task. The Golgi morphology is crucial in maintaining the function of transport proteins (such as GLUT1) driving glycolysis. Thus, in this study, we present a "Golgi-customized Trojan horse" based on tellurium loaded with apigenin (4',5,7-trihydroxyflavone) and human serum albumin, which was able to induce GLUT1 plasma membrane localization disturbance via Golgi dispersal leading to the inhibition of tumor glycolysis. Diamond-shaped delivery system can efficiently penetrate into cells as a gift like Trojan horse, which decomposes into tellurite induced by intrinsically high H
2 O2 and GSH levels. Consequently, tellurite acts as released warriors causing up to 3.8-fold increase in Golgi apparatus area due to the down-regulation of GOLPH3. Further, this affects GLUT1 membrane localization and glucose transport disturbance. Simultaneously, apigenin hinders ongoing glycolysis and causes significant decrease in ATP level. Collectively, our "Golgi-customized Trojan horse" demonstrates a potent antitumor activity because of its capability to deprive energy resources of cancer cells. This study not only expands the applications of tellurium-based nanomaterials in the biomedicine but also provides insights into glycolysis restriction for anticancer therapy., Competing Interests: Declaration of competing interest The authors declare no competing financial interest., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF